Severe immediate adverse events following immunization (AEFI) with COVID-19 vaccines have been reported in up to 2.5 per 10,000 vaccinations.¹ Differentiating allergic reactions from immunization stress-related responses (ISRR)² at the point of vaccination can be difficult, presenting an added burden to allergy clinics. Recent reports suggest that most individuals will tolerate mRNA re-vaccination in a supervised setting.^{3, 4} More information is needed to help predict those most likely to tolerate future vaccine doses, as excipient skin testing has provided a limited role.⁵

中文翻译：

---

对先前剂量有直接不良反应的患者进行 COVID-19 疫苗攻击的安全性：一项多中心队列研究

据报道，每 10,000 次疫苗接种中有多达 2.5 例发生 COVID-19 疫苗免疫接种后的严重即时不良事件 (AEFI)。¹在接种疫苗时区分过敏反应与免疫应激相关反应 (ISRR) ^{2可能很困难，这给过敏诊所带来了额外的负担。}最近的报告表明，大多数人会在受监督的环境中耐受 mRNA 再接种疫苗。^{3, 4}需要更多信息来帮助预测那些最有可能耐受未来疫苗剂量的人群，因为赋形剂皮肤测试的作用有限。^5个